Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.

Pahwa R, Tanner CM, Hauser RA, Isaacson SH, Nausieda PA, Truong DD, Agarwal P, Hull KL, Lyons KE, Johnson R, Stempien MJ.

JAMA Neurol. 2017 Aug 1;74(8):941-949. doi: 10.1001/jamaneurol.2017.0943.

2.

Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials.

Nausieda PA, Hsu A, Elmer L, Gil RA, Spiegel J, Singer C, Khanna S, Rubens R, Kell S, Modi NB, Gupta S.

J Parkinsons Dis. 2015;5(4):837-45. doi: 10.3233/JPD-150622.

3.

Quantitative analysis of tremors in welders.

Sanchez-Ramos J, Reimer D, Zesiewicz T, Sullivan K, Nausieda PA.

Int J Environ Res Public Health. 2011 May;8(5):1478-90. doi: 10.3390/ijerph8051478. Epub 2011 May 10.

4.

Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study.

Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L; Ease-PD Monotherapy Study Investigators.

Curr Med Res Opin. 2008 Oct;24(10):2883-95. doi: 10.1185/03007990802387130 . Epub 2008 Sep 2.

PMID:
18768106
5.

A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.

Nausieda PA, Pfeiffer RF, Tagliati M, Kastenholz KV, DeRoche C, Slevin JT.

Clin Ther. 2005 Jan;27(1):58-63. Erratum in: Clin Ther. 2005 Mar;27(3):360.

PMID:
15763606
6.

[18F]-Dopa positron emission tomography imaging in early-stage, non-parkin juvenile parkinsonism.

Pal PK, Leung J, Hedrich K, Samii A, Lieberman A, Nausieda PA, Calne DB, Breakefield XO, Klein C, Stoessl AJ.

Mov Disord. 2002 Jul;17(4):789-94.

PMID:
12210877
7.

Too many treatments for Parkinson's disease: how should they be used?

Nausieda PA.

WMJ. 2000 Aug;99(5):4. No abstract available.

PMID:
11043061
8.

Sinemet "abusers".

Nausieda PA.

Clin Neuropharmacol. 1985;8(4):318-27.

PMID:
4075303
9.

Psychiatric complications of levodopa therapy of Parkinson's disease.

Nausieda PA, Glantz R, Weber S, Baum R, Klawans HL.

Adv Neurol. 1984;40:271-7. No abstract available.

PMID:
6695603
10.

Chronic dopaminergic sensitivity after Sydenham's chorea.

Nausieda PA, Bieliauskas LA, Bacon LD, Hagerty M, Koller WC, Glantz RN.

Neurology. 1983 Jun;33(6):750-4.

PMID:
6188998
11.

Levodopa-free periods ("drug holidays") in the management of parkinsonism.

Klawans HL, Goetz CG, Tanner CM, Nausieda PA, Weiner WJ.

Adv Neurol. 1983;37:33-43. No abstract available.

PMID:
6858778
12.

Serotonergically active agents in levodopa-induced psychiatric toxicity reactions.

Nausieda PA, Tanner CM, Klawans HL.

Adv Neurol. 1983;37:23-32. No abstract available.

PMID:
6858774
13.

Parkinsonian features and progressive supranuclear palsy.

Weiner WJ, Nausieda PA.

Arch Neurol. 1982 Oct;39(10):672-3. No abstract available.

PMID:
7125989
14.

Meige's syndrome during long-term dopaminergic therapy in Parkinson's disease.

Weiner WJ, Nausieda PA.

Arch Neurol. 1982 Jul;39(7):451-2. No abstract available.

PMID:
7103786
15.
16.

Drug-induced asterixis in Parkinson disease.

Glantz R, Weiner WJ, Goetz CG, Nausieda PA, Klawans HL.

Neurology. 1982 May;32(5):553-5.

PMID:
7200212
17.

Modification of central serotonergic and dopaminergic behaviors in the course of chronic corticosteroid administration.

Nausieda PA, Carvey PM, Weiner WJ.

Eur J Pharmacol. 1982 Mar 12;78(3):335-43.

PMID:
6978254
18.

Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis.

Nausieda PA, Weiner WJ, Kaplan LR, Weber S, Klawans HL.

Clin Neuropharmacol. 1982;5(2):183-94.

PMID:
7139632
19.

Tardive dyskinesia: pharmacology and clinical implications.

Goetz CG, Weiner WJ, Nausieda PA, Klawans HL.

Clin Neuropharmacol. 1982;5(1):3-22. Review.

PMID:
7046923
20.

Effect of chronic levodopa on haloperidol-induced behavioral supersensitivity in the guinea pig.

Weiner WJ, Carvey P, Nausieda PA, Goetz CG, Klawans HL.

Adv Neurol. 1982;35:213-9. No abstract available.

PMID:
6890754
21.

Tourette-like symptoms following chronic neuroleptic therapy.

Klawans HL, Nausieda PA, Goetz CC, Tanner CM, Weiner WJ.

Adv Neurol. 1982;35:415-8. No abstract available.

PMID:
6128886
22.

Opsoclonic cerebellopathy: A paraneoplastic syndrome responsive to thiamine.

Nausieda PA, Tanner CM, Weiner WJ.

Arch Neurol. 1981 Dec;38(12):780-1. No abstract available.

PMID:
7316846
23.

Meige syndrome (blepharospasm-oromandibular dystonia) after long-term neuroleptic therapy.

Weiner WJ, Nausieda PA, Glantz RH.

Neurology. 1981 Dec;31(12):1555-6.

PMID:
6118844
24.

Weekly drug holiday in Parkinson disease.

Goetz CG, Tanner CM, Nausieda PA.

Neurology. 1981 Nov;31(11):1460-2.

PMID:
7031503
25.

Carbidopa-levodopa ratio in Parkinson's disease.

Weiner WJ, Nausieda PA.

Arch Neurol. 1981 Aug;38(8):534. No abstract available.

PMID:
7247796
26.

The effect of chronic levodopa on haloperidol induced behavioral supersensitivity in the guinea pig.

Weiner WJ, Carvey P, Nausieda PA, Goetz CG, Klawans HL.

Life Sci. 1981 May 11;28(19):2173-8. No abstract available.

PMID:
7195969
27.

Practical guidelines for drug holidays in parkinsonian patients.

Goetz CG, Nausieda PA, Weiner WJ, Klawans HL.

Neurology. 1981 May;31(5):641-2. No abstract available.

PMID:
7194987
28.

Complications of chronic levodopa therapy: long-term efficacy of drug holiday.

Koller WC, Weiner WJ, Perlik S, Nausieda PA, Goetz CG, Klawans HL.

Neurology. 1981 Apr;31(4):473-6.

PMID:
7194441
29.

Pemoline-induced chorea.

Nausieda PA, Koller WC, Weiner WJ, Klawans HL.

Neurology. 1981 Mar;31(3):356-60.

PMID:
7193830
30.

The effect of bromocriptine (BCT) on the on-off phenomenon.

Glantz R, Goetz CG, Nausieda PA, Weiner WJ, Klawans HL.

J Neural Transm. 1981;52(1-2):41-7.

PMID:
7026735
31.

Drug holiday and management of Parkinson disease.

Weiner WJ, Koller WC, Perlik S, Nausieda PA, Klawans HL.

Neurology. 1980 Dec;30(12):1257-61.

PMID:
7192805
32.

The pharmacological evaluation of pergolide mesylate as a potential anti-parkinson agent.

Koller WC, Weiner WJ, Diamond BI, Nausieda PA, Klawans HL.

Neuropharmacology. 1980 Sep;19(9):831-7. No abstract available.

PMID:
7191490
33.

Influence of female sex hormones on neuroleptic-induced behavioral supersensitivity.

Koller WC, Weiner WJ, Klawans HL, Nausieda PA.

Neuropharmacology. 1980 Apr;19(4):387-91. No abstract available.

PMID:
6104309
34.

Dystonic foot response of Parkinsonism.

Nausieda PA, Weiner WJ, Klawans HL.

Arch Neurol. 1980 Mar;37(3):132-6.

PMID:
7356417
35.

Sydenham chorea: an update.

Nausieda PA, Grossman BJ, Koller WC, Weiner WJ, Klawans HL.

Neurology. 1980 Mar;30(3):331-4.

PMID:
7189038
36.

Correlation between daily dosage of chlorpromazine and subsequent supersensitivity.

Klawans HL, Carvey P, Hitri A, Nausieda PA, Weiner WJ.

Adv Biochem Psychopharmacol. 1980;24:569-72. No abstract available.

PMID:
7190763
37.

Chorea induced by oral contraceptives.

Nausieda PA, Koller WC, Weiner WJ, Klawans HL.

Neurology. 1979 Dec;29(12):1605-9.

PMID:
574224
38.

Dopaminergic antagonism of L-5-hydroxytryptophan-induced myoclonic jumping behavior.

Weiner WJ, Carvey PM, Nausieda PA, Klawans HL.

Neurology. 1979 Dec;29(12):1622-5.

PMID:
41197
39.

Bromocriptine: decreased clinical effects at higher dosages.

Koller WC, Weiner WJ, Nausieda PA, Klawans HL.

Neurology. 1979 Oct;29(10):1439-40. No abstract available.

PMID:
573399
40.

Modification of postsynaptic dopaminergic sensitivity by female sex hormones.

Nausieda PA, Koller WC, Weiner WJ, Klawans HL.

Life Sci. 1979 Aug 6;25(6):521-6. No abstract available.

PMID:
573836
41.

Amphetamine-induced hypersensitivity in guinea pigs.

Weiner WJ, Goetz CG, Nausieda PA, Klawans HL.

Neurology. 1979 Jul;29(7):1054-7.

PMID:
572936
42.

Long-term prognosis in transient global amnesia.

Nausieda PA, Sherman IV.

JAMA. 1979 Jan 26;241(4):392-3.

PMID:
758558
43.

Effect of pergolide mesylate, an ergoline, in animal models of Parkinson's disease: implications for therapy.

Koller WC, Diamond BI, Weiner WJ, Nausieda PA, Klawans HL.

Trans Am Neurol Assoc. 1979;104:161-4. No abstract available.

PMID:
553398
44.

Clinical and experimental studies of phenytoin-induced hyperkinesias.

Nausieda PA, Koller WC, Weiner WJ, Klawans HL.

J Neural Transm. 1979;45(4):291-305.

PMID:
490152
45.

Levodopa-induced dopaminergic hypersensitivity in the pathogenesis of psychiatric and neurologic disorders.

Klawans HL, Moskovitz C, Nausieda PA, Weiner WJ.

Int J Neurol. 1979;13(1-4):225-36. No abstract available.

PMID:
263184
46.

Bromocriptine-induced behavioral hypersensitivity: implications for the therapy of parkinsonism.

Nausieda PA, Weiner WJ, Kanapa DJ, Klawans HL.

Neurology. 1978 Nov;28(11):1183-8.

PMID:
568738
47.

Methylphenidate-induced chorea: case report and pharmacologic implications.

Weiner WJ, Nausieda PA, Klawans HL.

Neurology. 1978 Oct;28(10):1041-4.

PMID:
570658
48.

Gilles de la Tourette syndrome after long-term chlorpromazine therapy.

Klawans HL, Falk DK, Nausieda PA, Weiner WJ.

Neurology. 1978 Oct;28(10):1064-6.

PMID:
284201
49.

Paradoxial response to dopaminergic agents in parkinsonism.

Wiener WJ, Kramer J, Nausieda PA, Klawans HL.

Arch Neurol. 1978 Jul;35(7):453-5.

PMID:
666596
50.

The effect of levodopa, lergotrile, and bromocriptine on brain iron, manganese, and copper.

Weiner WJ, Nausieda PA, Klawans HL.

Neurology. 1978 Jul;28(7):734-7.

PMID:
566875

Supplemental Content

Loading ...
Support Center